Clinical Trial Update: Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas [Phase 1]

View source ↗

Summary

The document reports the completion of a Phase 1 safety study evaluating veliparib (ABT-888) in combination with topotecan hydrochloride for patients with solid…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumor

Drugs mentioned

• Topotecan hydrochloride (topotecan hydrochloride)
• Veliparib (ABT-888) (veliparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Solid Tumors, Lymphomas | Phase 1 | Status: COMPLETED